Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Marizomib - Celgene Corporation

Next Previous
X
Search
Drug Profile

Marizomib - Celgene Corporation

Alternative Names: CC-92763; MRZ; NPI-0052; Salinosporamide A

Latest Information Update: 01 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nereus Pharmaceuticals
  • Developer Canadian Cancer Trials Group; Celgene Corporation; European Organisation for Research and Treatment of Cancer; National Cancer Institute (USA); Triphase Accelerator Corporation
  • Class Anti-inflammatories; Antineoplastics; Lactones; Pyrroles; Small molecules
  • Mechanism of Action Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II Ependymoma; Multiple myeloma
  • No development reported Diffuse intrinsic pontine glioma; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 03 Mar 2024 Dana-Farber Cancer Institute withdrawn phase-II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (IV, infusion) before enrolment due to study support withdrawn (NCT05050305)
  • 26 Feb 2024 Dana-Farber Cancer Institute terminates phase I trial in Diffuse intrinsic pontine glioma (In children, In adults, In adolescents, Monotherapy, Second-line therapy or greater) in USA (PO) due to withdrawal of support from BMS (NCT04341311)
  • 14 Feb 2024 Dana-Farber Cancer Institute terminates phase I trial in Glioma (In children, In adults, In adolescents, Combination therapy, Second-line therapy or greater) in USA (PO) due to withdrawal of support from BMS (NCT04341311)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top